BR-PROSPECT Radiolabeled Platelet Study

This is a platelet transfusion study. The primary purpose of this study is to determine if Biotin (vitamin B7) is an effective way to label platelets in survival and recovery studies. This study involves using a radioactive material as well as Biotin added to your platelets to track platelets in your blood. Your platelets will be collected using an apheresis procedure, labeled with biotin, and stored for 3 days. After the storage period, a radioactive material will be added to a small amount of your stored biotin-treated platelets. Your radiolabeled platelets will be given back to you and follow-up blood draws will be done to see how many of your platelets are circulating.

There will be a total of 12 visits over 180 days days. Each study visit lasts from 30 minutes to 3 hours.
Study visits will occur at Bloodworks Northwest – 1551 Eastlake Ave. East, Suite 100, Seattle, WA 98102.
Participants will be compensated up to $1500.00 for time involved in the study.

Participant Eligibility

Inclusion Criteria:
• At least 18 years of age.
• Be in good health.
• Weigh at least 114 lbs.
• Meet study criteria for an apheresis platelet collection.
• Not be taking medication known to interfere with platelet function such as aspirin, nonsteroidal anti-inflammatory drugs such as ibuprofen (Advil, Motrin) or naproxen (Aleve), or platelet inhibitors given for heart disease.
• Test negative for infectious diseases as part of blood donor screening.
Exclusion Criteria:
• Acute or chronic health conditions that may affect study results.
• Pregnant or nursing females.
• Test positive for cocaine or amphetamine use by urine drug screen test.
• Not have a spleen.
• History of known hypersensitivity to indium or chromium.
• On other investigation drug studies within the past 28 days.

Contact

Patricia Klotz
(206) 568-2238